Expertise in
1
conditions

Peter W. Nickerson

Winnipeg, MB, CA 
Expertise in
1
conditions
Winnipeg, MB, CA 
OverviewLocationsClinical Research

Overview

Peter Nickerson practices in Winnipeg, Canada. Mr. Nickerson is highly rated in 1 condition, according to our data. His top areas of expertise are Chronic Kidney Disease, Interstitial Nephritis, Acute Tubular Necrosis, Low Blood Pressure, and Kidney Transplant.

His clinical research consists of co-authoring 131 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Winnipeg, MB, Canada
Other Locations
MB, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Controlled Trial of Urine CXCL10 Chemokine Monitoring Post-renal Transplant
A Randomized Controlled Trial of Urine CXCL10 Chemokine Monitoring Post-renal Transplant
Enrollment Status: Active_not_recruiting
Publish Date: March 25, 2025
Intervention Type: Procedure
Study Phase: Phase 2/Phase 3
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Enrollment Status: Terminated
Publish Date: April 24, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 3
Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)
Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug, Biological
Study Drugs: Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Prednisone, Diphenhydramine
Study Phase: Phase 2
View 2 Less Clinical Trials

131 Total Publications

Antigen quantity is responsible for the discrepancy between phenotype and single antigen beads for the detection of human leukocyte antigen DQ antibody: Potential clinical implications.
Antigen quantity is responsible for the discrepancy between phenotype and single antigen beads for the detection of human leukocyte antigen DQ antibody: Potential clinical implications.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Published: January 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Nickerson's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile